Annual report pursuant to Section 13 and 15(d)

Reorganization and Recapitalization (Details) - Schedule of assets acquired and liabilities assumed, based on their fair values on acquisition date

v3.21.2
Reorganization and Recapitalization (Details) - Schedule of assets acquired and liabilities assumed, based on their fair values on acquisition date
Dec. 31, 2020
USD ($)
Reorganization and Recapitalization (Details) - Schedule of assets acquired and liabilities assumed, based on their fair values on acquisition date [Line Items]  
Cash $ 86,078
Prepaid expenses 722,455 [1]
Other receivables 420,000
Deposits 86,192
Property and equipment 47,958
Technology licenses 1,609,000 [2]
In process research and development 12,527,000 [2]
Due from (to) related parties 228,493
Accounts payable and accrued expenses (1,662,976)
Deferred income, related party (528,866) [3]
Deferred tax liabilities (3,677,180) [4]
Net fair value of assets acquired and liabilities assumed 9,858,154
Goodwill 36,278,344 [2]
Total 46,136,498
CBR Pharma [Member]  
Reorganization and Recapitalization (Details) - Schedule of assets acquired and liabilities assumed, based on their fair values on acquisition date [Line Items]  
Cash 47,268
Prepaid expenses 126,606 [1]
Other receivables
Deposits 86,192
Property and equipment 47,958
Technology licenses 1,609,000 [2]
In process research and development 1,584,000 [2]
Due from (to) related parties 783,593
Accounts payable and accrued expenses (1,528,894)
Deferred income, related party (36,537) [3]
Deferred tax liabilities (832,000) [4]
Net fair value of assets acquired and liabilities assumed 1,887,186
Goodwill 23,040,089 [2]
Total 24,927,275
180 [Member]  
Reorganization and Recapitalization (Details) - Schedule of assets acquired and liabilities assumed, based on their fair values on acquisition date [Line Items]  
Cash 38,810
Prepaid expenses 595,849 [1]
Other receivables 420,000
Deposits
Property and equipment
Technology licenses [2]
In process research and development 10,943,000 [2]
Due from (to) related parties (555,100)
Accounts payable and accrued expenses (134,081)
Deferred income, related party (492,329) [3]
Deferred tax liabilities (2,845,180) [4]
Net fair value of assets acquired and liabilities assumed 7,970,969
Goodwill 13,238,255 [2]
Total $ 21,209,224
[1] Includes $588,349 related to prepaid research and development expenses with Oxford University. See Note 14 – Commitments and Contingencies.
[2] Changes in the balance of technology licenses, in process research and development and goodwill reflected on the balance sheet are the result of the impact of the change in foreign currency exchange rates.
[3] Represents deferred income associated with the 360 Life Sciences Corp. agreement (formerly known as the “Reformation Pharmaceuticals” agreement). See Note 14 – Commitments and Contingencies.
[4] See Note 16 – Income Taxes for more information on deferred tax liabilities.